Prevalence of Incretin-Mimetic and Sodium-Glucose-Transporter-2-Inhibitor Therapy in German Hospitalized Type-2 Diabetic
- PDF / 443,863 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 93 Downloads / 146 Views
ORIGINAL RESEARCH
Prevalence of Incretin-Mimetic and Sodium-GlucoseTransporter-2-Inhibitor Therapy in German Hospitalized Type-2 Diabetics Following Myocardial Revascularization: An Observational Study Rainer U. Pliquett
. Linda Golle . Andreas Wienke .
Matthias Girndt
Received: September 5, 2020 / Accepted: October 21, 2020 The Author(s) 2020
ABSTRACT Introduction: Real-world data indicate that sodium glucose transporter-2–inhibitor therapy and/or incretin mimetics are not widely prescribed in type-2 diabetics with atherosclerotic vascular disease. We hypothesized that incretinmimetic therapy is associated with better overall survival and 1-year mortality in type-2 diabetics following myocardial revascularization. Methods: Hospitalized type-2 diabetics of the Departments of Cardiology and Cardiothoracic Surgery (University Hospital Halle) who needed myocardial revascularization (PCI or CABG) in 2016 were included in this observational study: group 1 (incretin-mimetic therapy), group 2 (insulin therapy without incretin mimetics) and group 3 (oral diabetes medication without incretins or insulin). They were asked to mail in a questionnaire on medical therapy and outcomes 1.9 years following discharge. In non-responders, vital status was obtained by local registration offices 2.4 years after discharge.
R. U. Pliquett (&) L. Golle M. Girndt Department of Internal Medicine II, University Hospital of the Martin Luther University HalleWittenberg, Halle, Germany e-mail: [email protected] A. Wienke Institute of Medical Epidemiology, Biometry and Informatics, Martin Luther University HalleWittenberg, Halle, Germany
Results: Two hundred four patients were recruited in this study. At discharge, only 4.4% of all type-2 diabetics were on incretin mimetic, 39.7% on insulin and 55.9% on oral diabetes medication. At the time of follow-up (response rate: 44.1%), there was no change in terms of prevalence of incretin-mimetic therapy (5.6% of responders). Prevalence of sodium glucose transporter-2–inhibitor therapy increased from 6.9% to 15.6% in responders. In-hospital mortality (group 1: 0%, group 2: 0%, group 3: 5.2%; p = 0.092), survival after discharge (group 1: 88.9%, group 2: 86.4%, group 3: 88.0%; p = 0.942) and number of rehospitalizations within 12 months after discharge (group 1: 1.0 per capita, group 2: 1.0, group 3: 1.1; p = 0.697) were similar among prespecified groups and between group 2 and 3. By 1.9-year follow-up, hypoglycemic events were more frequent in group 2 (1.5 ± 2.9) than in group 3 (0.02 ± 0.1; p = 0.0001). Conclusion: The prevalence of incretin mimetics and sodium-glucose-transporter-2 inhibitors was low both during the index hospitalization and at a 1.9-year follow-up. When comparing group 2 and group 3 patients, survival and rehospitalizations were similar; hypoglycemic events occurred more often in insulin-treated diabetics than in the those without. Keywords: Diabetes mellitus; Hypoglycemia; Incretin mimetics; Insulin; Sodium glucose transporter-2 inhibitors
Diabetes Ther
DIGITAL FE
Data Loading...
